But there are some warnings on the horizon. The drug pricing debate continues to ramp up and expand beyond the U.S., the side effects of Brexit and the U.S./China trade war are starting to show, and …
More Year in Review: From capital markets to CRISPR, 2019 a pretty good year for biopharma Videos